Atul Q2FY27: Consolidated PAT down 13% YoY to ₹159 Cr despite 21% revenue growth

Atul Ltd's consolidated revenue rose 21.0% YoY to ₹1,877.04 Cr for the quarter ended September 30, 2026, modestly ahead of the ~₹1,800 Cr we flagged pre-result. But consolidated PAT fell 13.0% YoY to ₹158.71 Cr — and 37.5% QoQ from Q1 FY27's ₹253.93 Cr — missing the ~₹235 Cr profit bar set out in our pre-result preview by a wide margin. Net profit margin compressed to 8.5% from 11.3% a year ago and 13.5% last quarter, below the 13-15% range the preview flagged as this quarter's test. No exceptional items are disclosed, so the decline is on a like-for-like basis (adjusted YoY PAT growth equals the reported -13.0%). The margin squeeze sits entirely in the segment mix. Performance and Other Chemicals (bulk chemicals, epoxy resins, adhesion promoters) delivered the growth — revenue up 31.3% YoY and 5.4% QoQ to ₹1,503.94 Cr — but segment profit fell 46.7% QoQ to ₹127.83 Cr even as revenue rose, implying a sharp cost or pricing squeeze on the added volume (segment margin fell to roughly 8.5% from about 16.8% in Q1). Life Science Chemicals (APIs and crop protection, the segment housing the phenoxy-herbicides capex flagged pre-result) moved the other way — both revenue (-2.9% YoY, -8.9% QoQ to ₹427.27 Cr) and segment profit (-31.0% YoY, -24.9% QoQ to ₹69.68 Cr) declined, meaning the capex-funded growth bet has not yet shown up in this quarter's numbers. We found no quarter-specific Street consensus for Q2 FY27 PAT; the only available read was the pre-result panel's Buy rating (11 analysts, ₹7,828 average target) and a broader FY27 full-year consensus PAT growth near 9.6%, well above what this single quarter shows. Standalone results tell a sharper version of the same story — PAT fell 17.9% YoY to ₹141.44 Cr on revenue of ₹1,623.46 Cr, a steeper drop than the consolidated print. Management has no formal guidance on record for this stock, so the quarter cannot be scored against a prior outlook, and no management press commentary on this print was available in our extracted materials at filing time. Alongside the results, the board approved a ₹90 Cr buyback (up to 1,20,000 shares, capped at ₹7,500/share) and appointed PwC as statutory auditor for FY28-32, succeeding Deloitte Haskins & Sells. Separately, the company's GPCB effluent-pipeline matter (clarified October 16, directions received October 19) falls after the September 30 quarter-end and is not reflected in these numbers, but is a live compliance item in the same operating footprint as the Performance and Other Chemicals segment. H1 FY27 consolidated PAT is still up 31.1% YoY (₹412.64 Cr vs ₹314.73 Cr), underscoring that the strength was front-loaded into Q1 and Q2 marks a sharp sequential deceleration rather than a full-year reversal. The quarter ahead will show whether the Performance and Other Chemicals margin squeeze is transient or structural, and whether the Life Science Chemicals capex-funded growth begins converting into volumes.